Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genzyme’s Head of Rare Diseases Honored by the Genetic Disease Foundation

Published: Tuesday, March 05, 2013
Last Updated: Tuesday, March 05, 2013
Bookmark and Share
Rogerio Vivaldi MD receives Industry Person of the Year.

Genzyme’s Head of Rare Diseases, Rogerio Vivaldi, MD, has been honored as the Genetic Disease Foundation’s Industry Person of the Year. The award is given to an individual in the life sciences industry who has made outstanding contributions to advancing medical research and bringing new therapies to people living with rare genetic diseases.

“For more than 20 years, Dr. Vivaldi has worked to identify the unmet needs of those living with rare genetic diseases, such as Gaucher disease,” said Elisa Ross, President of the Genetic Disease Foundation (GDF). “We are pleased to recognize Dr. Vivaldi for his dedication and commitment to improving patients’ lives.”

The award will be presented tonight at the GDF Gala at New York’s Gotham Hall. The event will raise funds for the Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai.

“I am truly honored by this award. As a physician in Brazil, I saw firsthand the importance of diagnosis and treatment for rare genetic diseases,” said Dr. Vivaldi. “At Genzyme we continue the mission to develop and deliver transformative therapies to all patients affected by rare genetic diseases.”

The Genetic Disease Foundation is a non-profit organization established in 1997 by patients and families affected by genetic disorders. The Foundation’s mission is to help prevent and treat genetic diseases by supporting research and counseling and conducting educational initiatives.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genzyme, Ablynx Launch MS Collaboration
Genzyme has agreed to use Ablynx's therapeutic proteins to carry out in vitro and in vivo research on multiple sclerosis models, then develop therapies against the disease.
Tuesday, May 19, 2015
Genzyme and Alnylam Expand Collaboration
Genzyme and Alnylam Pharmaceuticals have significantly expanded their strategic agreement to develop and commercialize treatments for rare genetic diseases.
Tuesday, January 14, 2014
Genzyme Celebrates Fifth Annual World MS Day
Company’s long-term commitment to MS extends beyond innovative therapies to new programs that address global needs of community.
Thursday, May 30, 2013
Genzyme Receives Company Award
Genzyme, announced that it has received a Company Award from EURORDIS, the largest European patient organization in the field of rare diseases.
Thursday, February 28, 2013
Genzyme’s LEMTRADA™ Application for MS Accepted for Review by the FDA
Genzyme also reports very encouraging early launch indicators for AUBAGIO® (teriflunomide) in U.S.
Tuesday, January 29, 2013
Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA™ for Multiple Sclerosis
Genzyme is developing LEMTRADA in MS in collaboration with Bayer HealthCare.
Wednesday, June 13, 2012
Genzyme's Biologics Support Center Achieves LEED Gold Rating for Environmentally Responsible Design
Site is Genzyme's tenth LEED-certified Green Building.
Friday, April 20, 2012
Genzyme and Veracyte Announce Global Co-Promotion Agreement
The companies announced the partnership will provide personalized and comprehensive solution for thyroid patients.
Monday, January 23, 2012
FDA Advisory Panel to Discuss Genzyme’s Myozyme BLA on Tuesday
Genzyme Corporation today announced that its U.S. Biologic License Application (BLA) for Myozyme® (alglucosidase alfa) produced at the 2000 L bioreactor scale will be discussed this Tuesday, October 21st, at a public meeting of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee in Silver Spring, Maryland.
Monday, October 20, 2008
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Four Newly-Identified Genes Could Improve Rice
A Japanese research team have applied a method used in human genetic analysis to rice and rapidly discovered four new genes that are potentially significant for agriculture. These findings could influence crop breeding and help combat food shortages caused by a growing population.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Antibodies To Dengue May Alter Course Of Zika Virus Infection
Scientists at Emory Vaccine Center, in collaboration with investigators from Thailand, have found that people infected with dengue virus develop antibodies that cross-react with Zika virus.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!